Tyler Van Buren
Stock Analyst at TD Cowen
(1.12)
# 3,421
Out of 4,829 analysts
57
Total ratings
29.41%
Success rate
-9.24%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | n/a | $25.54 | - | 1 | Jan 7, 2025 | |
| KROS Keros Therapeutics | Downgrades: Hold | n/a | $13.88 | - | 2 | Dec 12, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $75 | $20.37 | +268.19% | 2 | Nov 13, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | n/a | $14.05 | - | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | n/a | $9.72 | - | 1 | Sep 16, 2024 | |
| MRNA Moderna | Maintains: Hold | $70 → $60 | $25.66 | +133.83% | 6 | Sep 13, 2024 | |
| ARTV Artiva Biotherapeutics | Initiates: Buy | n/a | $2.17 | - | 1 | Aug 13, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | n/a | $10.44 | - | 1 | Aug 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,030 → $1,200 | $575.28 | +108.59% | 7 | Jul 23, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Buy | n/a | $20.65 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $19.12 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $85 | $104.01 | -18.28% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $37.85 | -20.74% | 2 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.08 | - | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.09 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $60.66 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.99 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.49 | - | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $21.69 | +38.31% | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $35.78 | - | 1 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.05 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $29.33 | +138.66% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.30 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.69 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.49 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.69 | +2,858.58% | 1 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $5.40 | +16,103.70% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $1.19 | +3,275.53% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.21 | +291.77% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $8.93 | +235.95% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $0.38 | +15,718.61% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.50 | +3,233.33% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.11 | +2,614.93% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $140 → $200 | $2.80 | +7,042.86% | 1 | Jan 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.06 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.83 | - | 1 | Aug 4, 2017 |
CG Oncology
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $25.54
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $13.88
Upside: -
Biohaven
Nov 13, 2024
Maintains: Buy
Price Target: $55 → $75
Current: $20.37
Upside: +268.19%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $14.05
Upside: -
Oruka Therapeutics
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $9.72
Upside: -
Moderna
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $25.66
Upside: +133.83%
Artiva Biotherapeutics
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $2.17
Upside: -
Cartesian Therapeutics
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $10.44
Upside: -
Regeneron Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $575.28
Upside: +108.59%
Tectonic Therapeutic
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $20.65
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $19.12
Upside: -
Apr 26, 2024
Maintains: Buy
Price Target: $90 → $85
Current: $104.01
Upside: -18.28%
Dec 11, 2023
Downgrades: Underperform
Price Target: $30
Current: $37.85
Upside: -20.74%
Dec 5, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.08
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $15.09
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $60.66
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $39.99
Upside: -
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.49
Upside: -
May 22, 2023
Initiates: Outperform
Price Target: $30
Current: $21.69
Upside: +38.31%
Feb 6, 2023
Initiates: Outperform
Price Target: n/a
Current: $35.78
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.05
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $29.33
Upside: +138.66%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.30
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.69
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.49
Upside: -
Mar 4, 2021
Initiates: Overweight
Price Target: $50
Current: $1.69
Upside: +2,858.58%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $5.40
Upside: +16,103.70%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $1.19
Upside: +3,275.53%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.21
Upside: +291.77%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $8.93
Upside: +235.95%
Jun 29, 2020
Initiates: Overweight
Price Target: $60
Current: $0.38
Upside: +15,718.61%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.50
Upside: +3,233.33%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $1.11
Upside: +2,614.93%
Jan 13, 2020
Reiterates: Overweight
Price Target: $140 → $200
Current: $2.80
Upside: +7,042.86%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $4.06
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $17.83
Upside: -